Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Review of bibliometric data shows growing research interest in macrophage polarization strategies for prostate cancer since 2015
Your Body's Immune Cells Could Fight Prostate Cancer Better
This bibliometric and visual analysis review examines publications related to macrophage polarization and activation in prostate cancer. The…
• Scientists reprogrammed immune cells to attack prostate tumors • Helps men with stubborn advanced prostate cancer • Still in early clinica…
Review of immunotherapy innovations for triple-negative breast cancer survival
New Hope for Tough-to-Treat Breast Cancer
This narrative review examines immunotherapy innovations, including immune checkpoint inhibitors and combination strategies, for patients wi…
This approach may change how doctors treat one of the hardest forms of breast cancer.
PARP inhibitors significantly improve progression-free survival in BRCA-mutated ovarian cancer patients
PARP Drugs Help BRCA Ovarian Cancer Patients Live Longer
This meta-analysis of 12 studies evaluated PARP inhibitor–based therapy in patients with BRCA-mutated ovarian cancer.
Women with BRCA-mutated ovarian cancer gain real survival time gains when using PARP inhibitors to delay cancer growth and stay cancer-free …
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier
Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …